Startups
Xlife Sciences AG builds the bridge from research and development to health care markets. We support researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, the firm takes projects a step further after an invention.
Subsequently, Xlife Sciences AG focuses on out-licensing or selling the company, often with a combination of a strategic partnership. The company offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage.
Subsequently, Xlife Sciences AG focuses on out-licensing or selling the company, often with a combination of a strategic partnership. The company offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage.
Overview
Location
Switzerland
Employees
11-50
Total raised
$5.43M
Founded date
2013
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 18
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Dec 23, 2025 | Xlife Sciences transitions from Sparks segment to main segment of SIX Swiss Exchange | Xlife Sciences AG today announced that its Board of Directors has resolved to move from the SIX Sparks segment to the main segment of the SIX Swiss Exchange. According to a press release, this step underscores the company’s strategic devel... |
| Dec 8, 2025 | Xlife Sciences AG announces exit of 12 project companies to Grupo Landsteiner | Under the agreement, Landsteiner will integrate Xlife Sciences’ platform technologies, biotech programs, medtech devices and AI-enabled solutions into its operations Together, Landsteiner and Xlife will align innovation, production and com... |
| Apr 23, 2025 | Veraxa plans to go public via SPAC at $1.64 billion valuation | VERAXA is a Swiss-based biopharmaceutical company advancing a premier drug discovery and development engine for ADCs and other novel antibody-based therapy concepts. The company originates from scientific discoveries made at the European M... |
| Oct 18, 2023 | 4D Lifetec secures CHF 23.3 million to enhance cancer diagnosis | |
| Feb 11, 2022 | Xlife Sciences AG: Xlife Sciences' shares begin trading on SIX Swiss Exchange | DGAP-Ad-hoc: Xlife Sciences AG / Key word(s): IPO Xlife Sciences AG: Xlife Sciences' shares begin trading on SIX Swiss Exchange 11-Feb-2022 / 07:13 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) N... |
| Feb 9, 2022 | Xlife Sciences AG: Xlife Sciences publishes prospectus for listing on SIX Swiss Exchange | DGAP-Ad-hoc: Xlife Sciences AG / Key word(s): IPO Xlife Sciences AG: Xlife Sciences publishes prospectus for listing on SIX Swiss Exchange 08-Feb-2022 / 22:56 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regula... |
| Feb 1, 2022 | Listing and first trading day on the 'Sparks' segment of SIX Swiss Exchange expected for February 11, 2022 | DGAP-Ad-hoc: Xlife Sciences AG / Key word(s): IPO Listing and first trading day on the 'Sparks' segment of SIX Swiss Exchange expected for February 11, 2022 01-Feb-2022 / 21:10 CET/CEST Disclosure of an inside information acc. to Article 17... |
| Jan 26, 2022 | Xlife Sciences raises CHF 5.0 million through capital increase | DGAP-Ad-hoc: Xlife Sciences AG / Key word(s): Capital Increase Xlife Sciences raises CHF 5.0 million through capital increase 26-Jan-2022 / 07:30 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No ... |
| Jan 10, 2022 | Xlife Sciences AG plans listing on the 'Sparks' segment of SIX Swiss Exchange | DGAP-Ad-hoc: Xlife Sciences AG / Key word(s): Regulatory Admission/Forecast Xlife Sciences AG plans listing on the 'Sparks' segment of SIX Swiss Exchange 10-Jan-2022 / 06:30 CET/CEST Disclosure of an inside information acc. to Article 17 MA... |
Show more
Reviews 0
FAQ about Xlife Sciences AG
When was Xlife Sciences AG founded?
Xlife Sciences AG was founded in 2013.
How much funding has Xlife Sciences AG raised?
Xlife Sciences AG has raised $5.43M in total across 1 funding round.
What has the press written about Xlife Sciences AG?
Parsers VC has collected 18 articles mentioning Xlife Sciences AG, among them “Xlife Sciences transitions from Sparks segment to main segment of SIX Swiss Exchange” (Dec 23, 2025) and “Xlife Sciences AG announces exit of 12 project companies to Grupo Landsteiner” (Dec 8, 2025).
Is Xlife Sciences AG still active?
Yes, Xlife Sciences AG is active; its latest activity on Parsers VC dates from Jun 12, 2026.